New spinal implant for kids with scoliosis under Long-Term safety review

NCT ID NCT07403084

Recruiting now Disease control Sponsor: EUROS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is tracking 140 children aged 5 to 17 with progressive scoliosis who receive the NEMOST V2 growing domino implant. The implant is designed to straighten the spine as the child grows. Researchers will monitor complications and how well the device works over 5 years after surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NEMOST V2 growing domino (spinal implant)
What this could lead to: If successful, this could confirm that the NEMOST implant is a safe and effective way to correct progressive scoliosis in growing children, reducing the need for repeated surgeries.
What could go wrong: This is an observational post-market study, not a randomized trial, so results may not prove the device is better than other treatments. Complications like infection or implant failure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONSENT FORMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic scoliosis scoliosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONSENT FORMS SCOLIOSIS IDIOPATHIC SCOLIOSIS NEUROMUSCULAR

Contacts and locations

Locations

CHU Pellegrin
RECRUITING

Bordeaux, France
Hopital Armand Trousseau
NOT_YET_RECRUITING

Paris, France
Hopital Lenval Nice
RECRUITING

Nice, Provence-Alpes-Côte d'Azur Region, 06000, France
Hopital Necker
NOT_YET_RECRUITING

Paris, France
Hospices Civils de Lyon
NOT_YET_RECRUITING

Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.